November 15, 2024
From the company website: MustGrow is an agriculture biotechnology company focused on developing and commercializing natural biological products and technologies from mustard for sustainable agriculture. These products and technologies are an alternative to banned/restricted synthetic chemicals and fertilizers for organic agriculture and to help improve soil health.
This small agricultural biotech company is the perfect RFK Jr-Trade. I invested in it four years ago after interviewing the management team of Corey Giasson (CEO) and Colin Bletsky (COO) at an investment conference. They are solid. https://mustgrow.ca/team/ I divested only because I correctly assessed Fed Quantitative Tightening (QT) ‘s negative impact on almost every small start-up company, which needs access to risk capital for its growth and survival. However, the chart shows that MustGrow did survive, and the financials show how quickly the company is growing.
Like every company, investing in MustGrow Biologics presents advantages and disadvantages for potential investors. Here’s an AI-generated summary:
Pros
- Strong Revenue Growth: MustGrow has demonstrated impressive revenue growth, with a reported increase of 98% annually over the past five years. This growth indicates a potentially expanding market presence and demand for its products4.
- Innovative Product Offering: The company focuses on developing organic biofertility products, particularly its flagship product, TerraSante™, which has received organic certification. This positions MustGrow favorably within the growing organic agriculture sector2.
- Market Expansion: Recent approvals for sales in California and exclusive distribution agreements in Oregon and Washington suggest that MustGrow is successfully expanding its market reach, which could lead to increased sales and brand recognition.
- Recent Share Performance: MustGrow has seen significant share price increases, including a 104% rise in the previous quarter, indicating positive market sentiment and potential investor interest.
Cons
- Lack of Profitability: The company has not reported a net loss of approximately $676,940 in the last year. This raises concerns about its financial health and ability to sustain operations long-term without consistent profits14.
- High Valuation Ratios: MustGrow’s price-to-sales ratio is notably high at 16.00, which may indicate that the stock is overvalued relative to its revenue. Investors should be cautious about paying a premium for growth that may not materialize1.
- Volatility Risks: The stock exhibits above-average volatility, leading to significant price fluctuations. This could pose risks for investors looking for stable returns1.
- Negative Cash Flow: The company generates negative cash flow from operations, suggesting challenges in covering operational costs through revenue alone. This could necessitate further financing or capital raises, potentially diluting existing shareholders.
In summary, while MustGrow Biologics offers promising growth prospects and innovative products in the organic sector, potential investors should weigh these benefits against concerns regarding profitability, valuation, and financial stability.
Several videos present the MustGrow case: https://www.youtube.com/playlist?list=PLnk_WM-WosgVvvy2dvqXBbUHmeZpuWzc1